Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX);

Grabar Law Office has announced investigations into DoubleVerify (DV), NAPCO Security Technologies (NSSC), Pacira Biosciences (PCRX), and Treace Medical Concepts (TMCI) concerning potential breaches of fiduciary duty and securities fraud. The investigations stem from allegations of misleading statements, undisclosed information regarding business operations, and internal control weaknesses which led to stock price declines; shareholders who held stock prior to specific dates are encouraged to seek corporate reforms and potential compensation.

Analysis

Grabar Law Office has initiated investigations and is publicizing ongoing securities class actions against four publicly traded companies—DoubleVerify Holdings, Inc. (DV), NAPCO Security Technologies, Inc. (NSSC), Pacira Biosciences, Inc. (PCRX), and Treace Medical Concepts, Inc. (TMCI)—citing potential breaches of fiduciary duty and securities fraud, contributing to a "strongly negative" sentiment (-0.8 overall, -0.9 for each named company). For DoubleVerify, allegations center on undisclosed challenges, including a shift in customer ad spending to closed platforms (e.g., Meta, Amazon) where DV's technology is limited and development costs for its high-margin Activation Services are significantly higher and more time-consuming than disclosed, alongside systematic overbilling and misleading risk disclosures; an InvestingPro AI analysis further noted DV was not a top-ranked undervalued stock. NAPCO Security Technologies faces a securities fraud class action that has survived a motion to dismiss, with key allegations pointing to unaddressed material weaknesses in internal controls over Cost of Goods Sold (COGS) and inventory, leading to erroneous unaudited financial statements (overstating inventory and understating net COGS) and necessitating restatements; the court found plaintiffs adequately pled scienter, supported by unusual officer stock sales totaling over $108 million, representing substantial portions of their holdings (48.5% and 45.5%). Pacira Biosciences is under scrutiny due to alleged misleading statements regarding the validity and scope of its patents, highlighted by the New Jersey District Court's invalidation of its ‘495 patent on August 9, 2024, which caused a dramatic stock price decline. Treace Medical Concepts is accused of making false and/or misleading statements by failing to disclose adverse facts about competition impacting demand for its Lapiplasty 3D Bunion Correction System, resulting in declining revenue and the need to accelerate alternative product plans. These legal actions collectively signal significant governance and operational concerns, potentially impacting the financial health and market perception of these companies.

Key Decisions for Investors

• Investors holding shares in DoubleVerify (DV), NAPCO Security Technologies (NSSC), Pacira Biosciences (PCRX), or Treace Medical Concepts (TMCI) should closely monitor the developments of these legal investigations and class action lawsuits, as outcomes could significantly impact shareholder value and company operations.
• For NAPCO Security Technologies, the survival of the motion to dismiss, coupled with allegations of material weaknesses in internal controls, impending financial restatements, and significant insider stock sales, warrants heightened scrutiny and a potential re-evaluation of risk exposure.
• Shareholders in Pacira Biosciences should assess the long-term impact of the ‘495 patent invalidation on its revenue streams and competitive positioning, while those in DoubleVerify and Treace Medical Concepts should critically examine the companies' disclosures regarding competitive pressures, product demand, and the true cost and timeline of strategic initiatives in light of the serious allegations.